Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer

Stopped The study will not resume based on the results of a planned interim analysis that showed futility

Conditions

• Ovarian Neoplasms

Interventions

• DRUG: Niraparib
• DRUG: Dostarlimab

Sponsor

Tesaro, Inc.

Collaborators

• [object Object]